DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Antonia S, Goldberg SB, Balmanoukian A. et al.
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Lancet Oncol 2016;
17: 299-308
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.